• Je něco špatně v tomto záznamu ?

Predictive Potential of Flow Cytometry Crossmatching in Deceased Donor Kidney Transplant Recipients Subjected to Peritransplant Desensitization

K. Osickova, P. Hruba, K. Kabrtova, J. Klema, J. Maluskova, A. Slavcev, J. Slatinska, T. Marada, GA. Böhmig, O. Viklicky

. 2021 ; 8 (-) : 780636. [pub] 20211214

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010449

Recipient sensitization is a major risk factor of antibody-mediated rejection (ABMR) and inferior graft survival. The predictive effect of solid-phase human leukocyte antigen antibody testing and flow cytometry crossmatch (FCXM) in the era of peritransplant desensitization remains poorly understood. This observational retrospective single-center study with 108 donor-specific antibody (DSA)-positive deceased donor kidney allograft recipients who had undergone peritransplant desensitization aimed to analyze variables affecting graft outcome. ABMR rates were highest among patients with positive pretransplant FCXM vs. FCXM-negative (76 vs. 18.7%, p < 0.001) and with donor-specific antibody mean fluorescence intensity (DSA MFI) > 5,000 vs. <5,000 (54.5 vs. 28%, p = 0.01) despite desensitization. In univariable Cox regression, FCXM positivity, retransplantation, recipient gender, immunodominant DSA MFI, DSA number, and peak panel reactive antibodies were found to be associated with ABMR occurrence. In multivariable Cox regression adjusted for desensitization treatment (AUC = 0.810), only FCXM positivity (HR = 4.6, p = 0.001) and DSA number (HR = 1.47, p = 0.039) remained significant. In conclusion, our data suggest that pretransplant FCXM and DSA number, but not DSA MFI, are independent predictors of ABMR in patients who received peritransplant desensitization.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010449
003      
CZ-PrNML
005      
20220425131832.0
007      
ta
008      
220420s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fmed.2021.780636 $2 doi
035    __
$a (PubMed)34970564
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Osickova, Klara $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia
245    10
$a Predictive Potential of Flow Cytometry Crossmatching in Deceased Donor Kidney Transplant Recipients Subjected to Peritransplant Desensitization / $c K. Osickova, P. Hruba, K. Kabrtova, J. Klema, J. Maluskova, A. Slavcev, J. Slatinska, T. Marada, GA. Böhmig, O. Viklicky
520    9_
$a Recipient sensitization is a major risk factor of antibody-mediated rejection (ABMR) and inferior graft survival. The predictive effect of solid-phase human leukocyte antigen antibody testing and flow cytometry crossmatch (FCXM) in the era of peritransplant desensitization remains poorly understood. This observational retrospective single-center study with 108 donor-specific antibody (DSA)-positive deceased donor kidney allograft recipients who had undergone peritransplant desensitization aimed to analyze variables affecting graft outcome. ABMR rates were highest among patients with positive pretransplant FCXM vs. FCXM-negative (76 vs. 18.7%, p < 0.001) and with donor-specific antibody mean fluorescence intensity (DSA MFI) > 5,000 vs. <5,000 (54.5 vs. 28%, p = 0.01) despite desensitization. In univariable Cox regression, FCXM positivity, retransplantation, recipient gender, immunodominant DSA MFI, DSA number, and peak panel reactive antibodies were found to be associated with ABMR occurrence. In multivariable Cox regression adjusted for desensitization treatment (AUC = 0.810), only FCXM positivity (HR = 4.6, p = 0.001) and DSA number (HR = 1.47, p = 0.039) remained significant. In conclusion, our data suggest that pretransplant FCXM and DSA number, but not DSA MFI, are independent predictors of ABMR in patients who received peritransplant desensitization.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hruba, Petra $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Kabrtova, Katerina $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Klema, Jiri $u Department of Computer Science, Faculty of Electrical Engineering, Czech Technical University, Prague, Czechia
700    1_
$a Maluskova, Jana $u Department of Pathology, Institute for Clinical and Experimental Medicine, Prague, Czechia $u Aesculab Pathology, Prague, Czechia
700    1_
$a Slavcev, Antonij $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Slatinska, Janka $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Marada, Tomas $u Department of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Böhmig, Georg A $u Division of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Vienna, Austria
700    1_
$a Viklicky, Ondrej $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia
773    0_
$w MED00188756 $t Frontiers in medicine $x 2296-858X $g Roč. 8, č. - (2021), s. 780636
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34970564 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220420 $b ABA008
991    __
$a 20220425131830 $b ABA008
999    __
$a ind $b bmc $g 1784597 $s 1161647
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 8 $c - $d 780636 $e 20211214 $i 2296-858X $m Frontiers in medicine $n Front. med. $x MED00188756
LZP    __
$a Pubmed-20220420

Najít záznam

Citační ukazatele

Možnosti archivace